Ethyl 3-hydroxy-4,5,6,7-tetrahydro-1H-indole-2-carboxylate, 98%, 5g

[(Tetrahydro-2H-pyran-4-yl)methyl]hydrazine dihydrochloride, 95+%, 250mg

N-(2-Hydrazino-2-oxoethyl)-N-methylmethanesulfonamide, 95.0%, 5g

2-Oxo-6-(trifluoromethyl)-1,2-dihydropyridine-4-carboxylic acid, 97%, 250mg

4,6-Dichloropyridine-2-carbonitrile, 95.0%, 250mg

(2S,4S)-4-(tert-butoxy)-1-[(9H-fluoren-9-ylmethoxy)carbonyl]pyrrolidine-2-carboxylic acid, 95.0%, 10g

(3R,4S)-4-(4-(Benzyloxy)phenyl)-1-(4-fluorophenyl)-3-(3-(4-fluorophenyl)-3-oxopropyl)azetidin-2-one, 98%, 25g

(S)-(-)-1-Phenylethylamine>98.0%(GC)25mL

GC capillary column ROTI®Cap-5, 60 m, 0.32 mm, 3.00 µm, 1 Piece(s)

4-(Benzo[d]oxazol-2-yl)phenol, 95+%, 500mg

(1S)-8-azaspiro[bicyclo[3.2.1]octane-3,4'-imidazolidine]-2',5'-dione hydrochloride, 95%, 1g

4-Nitrocatechol sulfate (dipotassium salt), 98%, 1g

2-Fluoro-4-methylbenzenethiol, 5g